Treatment of female sexual dysfunction
US5945117A · kind A · utility
41Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 1998 |
| Grant date | Aug 31, 1999 |
| Priority date | — |
| Expiry date | Jan 30, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sexual dysfunction in human females can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter is preferably maintained.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.